Salmonella (e.g., Salmonella Typhimurium, Etc.) Patents (Class 424/258.1)
  • Patent number: 7887816
    Abstract: The present invention pertains to a Salmonella microorganism having an attenuating mutation which disrupts the expression of a gene located within the Spi2 pathogenicity island, and an auxotrophic mutation. The microorganism therefore has a double mutation which helps prevent reactivity of the microorganism while maintaining the effectiveness of the microorganism to elicit an immune response. The present invention also pertains to vaccine compositions and methods for treating and preventing a Salmonella infection in a patient.
    Type: Grant
    Filed: February 1, 2007
    Date of Patent: February 15, 2011
    Assignee: Emergent Product Development UK Limited
    Inventors: Robert Graham Feldman, Gordon Dougan, Joseph David Santangelo, David William Holden, Jacqueline Elizabeth Shea, Zoe Hindle
  • Publication number: 20110033501
    Abstract: The present invention relates to a recombinant bacterium that is capable of eliciting an immune response against at least two enteric pathogens, without substantially inducing an immune response specific to the serotype of the bacterium. The invention also relates to methods of making such a bacterium and vaccines and methods of using such a bacterium.
    Type: Application
    Filed: October 6, 2008
    Publication date: February 10, 2011
    Applicant: The Arizona Board of Regents for and on behalf of Arizona State University
    Inventors: Roy Curtiss iii, Melha Mellata, Bereket Zekarias, Zhaoxing Shi, Christine Branger, Kenneth Roland
  • Publication number: 20110027309
    Abstract: Provided herein are Salmonella enteritidis 13A strains and compositions comprising these strains. Also provided are methods of enhancing an immune response against Influenza A and methods of reducing morbidity associated with an Influenza A infection. Methods of enhancing an immune response to a vaccine vector by expressing a polypeptide of CD 154 capable of binding CD40 are also disclosed. Methods of developing a bacterial vaccine vector are disclosed. Methods of generating scarless site-specific mutations in a bacterium are also disclosed.
    Type: Application
    Filed: September 18, 2007
    Publication date: February 3, 2011
    Inventors: Walter Bottje, Billy Hargis, Luc Berghman, Young Min Kwon, Kimberly Cole, Mandy Cox, Sherryll Layton
  • Patent number: 7871604
    Abstract: Disclosed is an Environmentally Limited Viability System (ELVS) for microorganisms based on temperature differences between permissive and non-permissive environments. Viability of the microorganisms are limited to the permissive environment by specifically expressing one or more essential genes only in the permissive environment, or expressing one or more lethal genes only in the non-permissive environment. Environmentally Limited Viability Systems are also disclosed involving coordinate expression of a combination of required genes and lethal genes. Microorganisms containing an Environmentally Limited Viability System are useful for release into a permissive environment. Temperature regulated Environmentally Limited Viability Systems are particularly suited for use with recombinant avirulent Salmonella vaccines by limiting their growth to the warmer environment inside the host.
    Type: Grant
    Filed: July 22, 1998
    Date of Patent: January 18, 2011
    Assignee: Washington University
    Inventors: Roy Curtiss, III, Steven A. Tinge
  • Publication number: 20100330124
    Abstract: The present invention provides a novel immunogenic composition, vaccine and methods for making and using the immunogenic composition and vaccine. The immunogenic composition is capable of providing an immune response and/or a protective immunity into subjects, preferably mammals, against microorganism-associated disease. The immunogenic composition includes one or more extracellular proteins isolated from a microorganism capable of providing an immune response and/or a protective immunity into subjects against microorganism-associated disease. The isolated extracellular proteins range in molecular weight from about 10,000 Da to about 220,000 Da. Suitable microorganisms may include members of the genus Salmonella, Listeria, Pseudomonas, Staphylococcus, and Vibrio. Kits are also encompassed for detection, diagnosis and prevention of microorganism-associated disease.
    Type: Application
    Filed: June 23, 2010
    Publication date: December 30, 2010
    Inventor: Richard E. COWART
  • Publication number: 20100284963
    Abstract: Immunogenic compositions comprising growth regulatable recombinant intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens are provided. Exemplary immunogenic compositions include, but are not limited to, growth regulatable and growth limited recombinant intracellular pathogen immunogenic compositions.
    Type: Application
    Filed: April 10, 2007
    Publication date: November 11, 2010
    Inventors: Marcus A. Horwitz, Michael V. Tullius
  • Publication number: 20100285064
    Abstract: The present invention provides a Withania somnifera fraction rich in withanolides and a vaccine comprising a “Withania somnifera fraction” as an adjuvant.
    Type: Application
    Filed: May 5, 2010
    Publication date: November 11, 2010
    Applicant: SERUM INSTITUTE OF INDIA LTD.
    Inventors: Suresh Sakharam Jadhav, Bhushan Patwardhan, Manish Gautam
  • Publication number: 20100278857
    Abstract: The present invention provides novel peptides which specifically targets and binds to dendritic cells. Also provided are fusion compositions comprising these peptides and a non-dendritic protein of fragments thereof. Further provided are DNA sequences encoding these peptides and fusion compositions. Methods of using the peptides or fusion compositions to promote an immune responses in an individual via administration also are provided.
    Type: Application
    Filed: April 8, 2004
    Publication date: November 4, 2010
    Applicant: ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    Inventors: Mansour Mohamadzadeh, Tyler J. Curiel, Cindy A. Morris
  • Publication number: 20100272758
    Abstract: The present invention provides non-toxic Gram-negative bacteria. In particular, the present invention provides viable Gram-negative bacteria (e.g., E. coli) substantially lacking lipopolysaccharide (LPS, endotoxin) within the outer membrane. The present invention further provides methods of generating viable non-toxic Gram-negative bacteria and uses thereof. The present invention also provides compositions and methods for inducing immune responses and for researching and developing therapeutic agents.
    Type: Application
    Filed: January 19, 2007
    Publication date: October 28, 2010
    Applicant: Regents of the University of Michigan
    Inventors: Ronald Wesley Woodard, Timothy Charles Meredith, Parag Aggarwal
  • Publication number: 20100260794
    Abstract: The present invention relates to attenuated guaB deletion mutants of a bacterium infecting veterinary species, more in particular Salmonella enterica, to their use and production. The present invention further relates to live attenuated vaccines based on such mutants for preventing bacterial infections, and more in particular Salmonellosis, in a veterinary species, more in particular poultry.
    Type: Application
    Filed: March 20, 2006
    Publication date: October 14, 2010
    Inventors: Henri Marcel Jozef De Greve, Connie Theresia Adriaensen, Jean-Pierre Ernest Clement Hernalsteens
  • Publication number: 20100255036
    Abstract: The invention provides an attenuated enterobacterium comprising an attenuating mutation in the fnr gene, and optionally further comprising a heterologous nucleic acid encoding a foreign antigen. Also provided are pharmaceutical formulations comprising the attenuated enterobacteria of the invention. Further disclosed are methods of inducing an immune response in a subject by administration of an immunogenically effective amount of an attenuated enterobacterium or pharmaceutical formulation of the invention.
    Type: Application
    Filed: July 9, 2009
    Publication date: October 7, 2010
    Inventors: Hosni M. Hassan, Ryan C. Fink, Matthew R. Evans
  • Patent number: 7807139
    Abstract: The present invention provides a method for the treatment and/or prevention of bacterial infection caused by Klebsiella pneumoniae and other gram-negative bacteria in central nervous system and/or peripheral blood circulation in a mammal by administering effective amount of outer membrane protein A (OmpA) or its derivatives to a mammal. Also provided are a method for vaccinating a mammal to produce an antibody against bacterial infection caused by Enterobacteriaceae family in central nervous system and/or peripheral blood circulation and a method of detecting or diagnosing bacterial infections caused by Enterobacteriaceae family in central nervous system and/or peripheral blood circulation in a mammal.
    Type: Grant
    Filed: January 23, 2009
    Date of Patent: October 5, 2010
    Assignee: Taipei Medical University
    Inventors: Yi-Yuan Yang, Hsueh-Hsia Wu, Sy-Jye Leu, Neng-Yao Shih, I-Jen Huang, Ching-Yu Lin, Wen-Shyang Hsieh, Ko-Jiunn Liu, Shih-Yi Huang, Yueh-Lun Lee, Chi-Hsin Lee, Yuan-Soon Ho, Shih-Lan Hsu
  • Publication number: 20100247537
    Abstract: Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (?-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is also provided.
    Type: Application
    Filed: April 25, 2008
    Publication date: September 30, 2010
    Inventors: Cory Ahonen, Randolph Noelle
  • Patent number: 7790183
    Abstract: This invention relates to a method for coating a medical device comprising the steps of applying to at least a portion of the surface of said medical device, an antimicrobial coating layer and a non-pathogenic bacterial coating layer, wherein the antimicrobial and non-pathogenic bacterial coating layers inhibit the growth of pathogenic bacterial and fungal organisms. The non-pathogenic bacterium used in the bacterial coating layer is resistant to the antimicrobial agent. Furthermore, the non-pathogenic bacterium layer includes at least one of the following: viable whole cells, non-viable whole cells, or cellular structures or extracts. The antimicrobial agent and non-pathogenic bacterium are used to develop a kit comprising these compositions in one container or in separate containers. The kit is used to coat a catheter prior to implantation in a mammal.
    Type: Grant
    Filed: February 26, 2004
    Date of Patent: September 7, 2010
    Assignee: Baylor College of Medicine
    Inventors: Rabih O. Darouiche, Richard Hull
  • Publication number: 20100215679
    Abstract: The disclosure provides an antigenic composition useful for immunization against tularemia. The disclosure provides a method for producing a vaccine for preventing tularemia in humans and animals, a new vaccine against tularemia in humans and animals, and a new approach to producing vaccines against tularemia.
    Type: Application
    Filed: October 22, 2007
    Publication date: August 26, 2010
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Marcus A. Horwitz, Qingmei Jia, Bai-Yu L. Clemens, Daniel Clemens
  • Patent number: 7780966
    Abstract: An artificial invasin complex is prepared from purified or recombinantly prepared invasins and gram negative bacteria lipopolysaccharides. Typically, IpaB is mixed with IpaC to form a IpaB:IpaC complex. This invasin protein complex is then mixed with the lipopolysaccharide to form an artificial invasin complex. Additional bioactive molecules can be incorporated into the complex during manufacture. This artificial invasin complex is similar in function to native Invaplex 24 or Invaplex 50. The artificial invasin complex has superior immunogenicity properties relative to the native complex and can be tailor made. Its method of preparation lends itself to scale up. The artificial invasin complex can facilitate transport of biomolecules, therapeutics and antibiotics across cell membranes in a manner similar to native Shigella Invaplex.
    Type: Grant
    Filed: March 27, 2007
    Date of Patent: August 24, 2010
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Edwin V. Oaks, Kevin R. Turbyfill, Robert W. Kaminski
  • Publication number: 20100196416
    Abstract: A typhoid vaccine using heat shock protein (Hsp) of Salmonella typhi and a method for the manufacture thereof. A method of administering a composition comprising an effective amount of a complex consisting of a Hsp, in part or whole, either alone or covalently or non-covalently bound to an antigenic molecule, which when administered elicits specific immunological responses in the host is also describe. The Antigenic molecule refers to the exogenous antigens/immunogens viz LPS, peptide, nucleic acid or polysaccharide or antigenic/immunogenic fragments and derivatives thereof.
    Type: Application
    Filed: October 4, 2006
    Publication date: August 5, 2010
    Inventors: Mustoori Sairam, Anju Bansal, Sarada S. Surya Kumari, Piyush Paliwal
  • Patent number: 7754227
    Abstract: This invention relates to conjugates of the Vi polysaccharide of S. typhi with the carrier Pseudomonas aeruginosa recombinant exoprotein A (rEPA), and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, S. typhi bacterial infections. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies against S. typhi and are useful to prevent and/or treat illnesses caused by S. typhi.
    Type: Grant
    Filed: March 20, 2007
    Date of Patent: July 13, 2010
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Zuzana Kossaczka, Shousun Chen Szu, John B. Robbins, Rachel Schneerson, Joseph Shiloach
  • Publication number: 20100136058
    Abstract: A DNA vaccine suitable for eliciting an immune response against cancer cells comprises a polynucleotide construct operably encoding an a Fra-1 protein, such as a polyubiquitinated human Fra-1 protein, and IL-18, such as human IL-18, in a pharmaceutically acceptable carrier. In a preferred embodiment, the polynucleotide construct is operably incorporated in an attenuated bacterial vector, such as an attenuated Salmonella typhimurium, particularly a doubly attenuated aroA- dam- S. typhimurium. Transformed host cells, methods of inhibiting tumor growth, of vaccinating a patient against cancer, and of delivering genetic material to a mammalian cell in vivo are also described.
    Type: Application
    Filed: August 4, 2009
    Publication date: June 3, 2010
    Inventors: Yunping Luo, Rong Xiang, Ralph A. Reisfeld
  • Publication number: 20100136060
    Abstract: The present invention relates to the use of an immunogenic composition that comprises a salmonella antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection, even more preferably PCVAD. The use relates to a method comprising the steps of administering the composition to an animal in need thereof, preferably prior to disease exposure. Administration of salmonella antigen, preferably a salmonella vaccine, lessens the incidence and reduces the severity of PCVAD.
    Type: Application
    Filed: November 21, 2007
    Publication date: June 3, 2010
    Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.
    Inventor: John Kolb
  • Publication number: 20100062019
    Abstract: The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified or weakly purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group comprising an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof.
    Type: Application
    Filed: September 10, 2009
    Publication date: March 11, 2010
    Inventors: Alexis Guy Andre Parisot, Stephanie Marie-Catherine Desgouilles-Blechet, Catherine Charreyre
  • Patent number: 7674467
    Abstract: The present invention is directed to isolated Salmonella bacteriophage, and methods of using Salmonella bacteriophage, or polynucleotides and polypeptides derived therefrom, to control the growth or contamination of food products by Salmonella. The present invention also contemplates the use of Salmonella bacteriophage, and polynucleotides and polypeptides derived therefrom, for the treatment of host infections or environmental contamination by Salmonella.
    Type: Grant
    Filed: September 3, 2004
    Date of Patent: March 9, 2010
    Assignee: Intralytix, Inc.
    Inventors: Alexander Sulakvelidze, Shanmuga Sozhamamnnan, Gary R. Pasternack
  • Patent number: 7655241
    Abstract: The present invention concerns the use of methods and compositions to prophylactically or therapeutically vaccinate a subject against a pathogen or disease. Embodiments of the invention include the production of an attenuated bacterium from the family Enterobacteriaceae with a non-functional lipoprotein for use as a vaccine or as a vaccine vector for delivering antigens to a subject to be vaccinated. In certain embodiments, a bacterium of the Enterobacteriaceae family lacking a wild type LP, for example Salmonella typhimurium lacking a wild type LP, may be produced and used as a vaccine or vaccine vector.
    Type: Grant
    Filed: March 20, 2003
    Date of Patent: February 2, 2010
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Gary R. Klimpel, David W. Niesel, Ashok Chopra, Jian Sha
  • Publication number: 20100003284
    Abstract: A live attenuated bacterium of the genus Escherichia, Salmonella or Yersinia, said bacterium being incapable of expressing a functional Eda protein as a result of a mutation in the eda gene and a vaccine comprising the live attenuated bacterium.
    Type: Application
    Filed: August 26, 2004
    Publication date: January 7, 2010
    Applicant: THE BOARD OF GOVERNORS FOR HIGHER EDUCATION, STATE OF PHODE ISLAND AND PROVIDENCE PLANTATIONS
    Inventor: Paul S. Cohen
  • Publication number: 20090324642
    Abstract: A method for eliciting or inducing an immune response in a human or animal subject, comprises administering to said subject a composition comprising an antigen and an adjuvant, wherein the composition is administered to the subject by the intra-lung route.
    Type: Application
    Filed: August 31, 2007
    Publication date: December 31, 2009
    Inventors: Stirling John Edwards, Martin John Pearse, Jean-Pierre Yves Scheerlinck, Philip Sutton
  • Publication number: 20090297561
    Abstract: The invention provides methods of generating phage lysate bacterins, as well as phage lysate bacterin compositions. The invention further encompasses methods of vaccination comprising administering phage lysate bacterin to an animal in need thereof. The invention further encompasses methods of reducing infection or colonization of poultry or poultry eggs using phage bacterin lysates. Method of vaccination comprising administering to an animal in need of immunization an amount of phage lysate bacterin to induce an immune response.
    Type: Application
    Filed: September 3, 2004
    Publication date: December 3, 2009
    Applicant: Intralytix
    Inventors: Gary R. Pasternack, Alexander Sulakvelidze, Torrey Brown
  • Publication number: 20090280145
    Abstract: The present invention relates to an immunogen-carrier having immunopotentiating or adjuvant properties. More particularly, the immunogen-carrier is a virus-like particle (VLP) from the family of potexvirus, and most particularly the papaya mosaic virus. The VLP produced by recombinant techniques is in fusion with one of its own proteins a protein immunogen. The above VLP and a protein or a protein extract from a viral, bacterial or parasital pathogen may be used as a vaccine.
    Type: Application
    Filed: April 3, 2009
    Publication date: November 12, 2009
    Inventors: Denis Leclerc, Constantino Roberto Lopez-Macias
  • Patent number: 7608247
    Abstract: The present invention provides a method for the treatment and/or prevention of bacterial infection in central nervous system and/or peripheral blood circulation in a mammal by administering effective amount of outer membrane protein A (OmpA) or its derivatives to a mammal. Also provided is an antibody binding to OmpA that can assay OmpA levels in a biological sample and detect or diagnose bacterial infection in central nervous system and/or peripheral blood circulation.
    Type: Grant
    Filed: March 11, 2008
    Date of Patent: October 27, 2009
    Assignee: Taipei Medical University
    Inventors: Yi-Yuan Yang, Hsueh-Hsia Wu, Sy-Jye Leu, I-Jen Huang, Neng-Yao Shih, Ko-Jiunn Liu, Mei-Ru Chen, Wen-Shyang Hsieh, Chi-Hsin Lee
  • Publication number: 20090263419
    Abstract: A live, attenuated bacterium of the genus Escherichia, Yersinia or Salmonella, that does not have a functional tRNA5leu, and vaccines comprising the live, attenuated bacterium.
    Type: Application
    Filed: May 21, 2009
    Publication date: October 22, 2009
    Applicant: The Board of Governers for Higher Education, State of Rhode Island and Providence Plantations
    Inventor: Paul S. Cohen
  • Publication number: 20090232852
    Abstract: The present invention provides a method for the treatment and/or prevention of bacterial infection caused by klebsiella pneumoniae and other gram-negative bacteria in central nervous system and/or peripheral blood circulation in a mammal by administering effective amount of outer membrane protein A (OmpA) or its derivatives to a mammal. Also provided are a method for vaccinating a mammal to produce an antibody against bacterial infection caused by Enterobacteriaceae family in central nervous system and/or peripheral blood circulation and a method of detecting or diagnosing bacterial infections caused by Enterobacteriaceae family in central nervous system and/or peripheral blood circulation in a mammal.
    Type: Application
    Filed: January 23, 2009
    Publication date: September 17, 2009
    Applicant: Taipei Medical University
    Inventors: Yi-Yuan Yang, Hsueh-Hsia Wu, Sy-Jye Leu, Neng-Yao Shih, I-Jen Huang, Ching-Yu Lin, Wen-Shyang Hsieh, Ko-Jiunn Liu, Shih-Yi Huang, Yueh-Lun Lee, Chi-Hsin Lee, Yuan-Soon Ho, Shih-Lan Hsu
  • Publication number: 20090208534
    Abstract: The invention relates to an attenuated Salmonella sp. that is capable of targeting a solid tumor when administered in vivo comprising a short hairpin (sh) RNA construct, and methods of inhibiting the growth or reducing the volume of a solid tumor cancer comprising administering an effective amount of an attenuated Salmonella sp. to a patient having a solid tumor cancer, wherein said attenuated Salmonella sp. is a tumor targeting attenuated Salmonella sp. expressing a short hairpin (sh) RNA which attenuated Salmonella sp. is capable of inhibiting the growth or reducing the volume of the solid tumor cancer when administered in vivo.
    Type: Application
    Filed: July 24, 2007
    Publication date: August 20, 2009
    Applicant: The Government of The United States of America, as represented by the Secretary, Dept.of Health
    Inventors: Deqi Xu, Dennis J. Kopecko, Jiadi Hu, Ling Zhang, Xuejian Zhao, Lifang Gao
  • Publication number: 20090181054
    Abstract: The present invention describes derivatized polysaccharide-protein conjugates, a composition comprising one or more of such derivatized polysaccharide-protein conjugates and methods of immunizing human patients with the same. The derivatized polysaccharide-protein conjugates are purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y, derivatized chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains.
    Type: Application
    Filed: March 2, 2009
    Publication date: July 16, 2009
    Inventor: Robert P. Ryall
  • Publication number: 20090175913
    Abstract: The invention concerns novel Salmonella enterica attenuated strains, characterized in that they are inactivated at the level of the znuABC operon through mutation in at least one of the znuA, znuB, znuC genes of such operon, for uses in medical or veterinary fields as vaccines.
    Type: Application
    Filed: June 8, 2007
    Publication date: July 9, 2009
    Inventors: Serena Ammendola, Andrea Battistoni, Paolo Pasquali
  • Publication number: 20090162402
    Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.
    Type: Application
    Filed: February 26, 2009
    Publication date: June 25, 2009
    Applicant: Epitopix, LLC
    Inventors: Daryll A. Emery, Darren E. Straub, Donavan E. Zammert, Gayla K. Kallevig
  • Patent number: 7541043
    Abstract: Compositions and methods for protecting a susceptable host against an infection of Shigella sonnei are disclosed. Such compositions and methods are useful for protecting the host against bacillary dysentery and shigellosis.
    Type: Grant
    Filed: January 15, 2003
    Date of Patent: June 2, 2009
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Dennis J. Kopecko, De-Qi Xu, John O. Cisar
  • Publication number: 20090136623
    Abstract: The present invention relates to growth-inhibitory composition against pathogenic bacteria of meat based food stuff comprising IgY, a specific immunoglobulin derived from yolk of egg. The 12 representative bacteria and other microbes deteriorating quality of process meat products that the IgY of the present invention targets include Aeromonas hydrophila, Bacilluis cereus, Campylobacter jejuni, Clostridium perfringens, 0157: H7 (Escherichia coli 0157:H7), Lactobacillus, Listeria monocytogens, Sacromyces cerevisae, Salmonella enteritidis, Salmonella typhimurium, Staphylococcus aureus, and Staphylococcus epidermidis. As the form of antigen, the 12 bacteria are injected to chickens separately to obtain IgY of the present invention against the 12 pathogens.
    Type: Application
    Filed: March 12, 2007
    Publication date: May 28, 2009
    Inventor: Min-Seok SONG
  • Publication number: 20090123500
    Abstract: The invention provides a vaccine for immunizing poultry and other animals against infection by a gram-negative bacteria, and a method of immunizing an animal using the vaccine. The vaccine may contain purified siderophore receptor proteins derived from a single strain or species of gram-negative bacteria or other organism, which are cross-reactive with siderophores produced by two or more strains, species or genera of gram-negative bacteria. The invention further provides a process for isolating and purifying the siderophore receptor proteins, and for preparing a vaccine containing the proteins. Also provided is a method for diagnosing gram-negative sepsis.
    Type: Application
    Filed: December 31, 2008
    Publication date: May 14, 2009
    Applicant: Epitopix, LLC
    Inventors: Daryll A. Emery, Darren E. Straub
  • Patent number: 7514089
    Abstract: The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The present invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors.
    Type: Grant
    Filed: April 28, 2005
    Date of Patent: April 7, 2009
    Assignee: Vion Pharmaceuticals, Inc.
    Inventors: David Bermudes, Kenneth Brooks Low
  • Publication number: 20090081257
    Abstract: The present disclosure describes pathogenic bacteria that have been modified to be deficient in NiFe hydrogenase activity; compositions comprising such modified bacteria, and the use of such bacteria to protect animals from pathogenic enteric bacterial infections.
    Type: Application
    Filed: February 28, 2005
    Publication date: March 26, 2009
    Inventors: Robert J. Maier, John S. Gunn
  • Publication number: 20090017073
    Abstract: A method for modulating Nod1 activity wherein said method comprises the steps of providing cells expressing a functional Nod1: and bringing said cells into contact with a molecule related to compositions comprising a molecule related to MTP and use of a molecule related to MTP for modulating inflammation and/or apoptosis.
    Type: Application
    Filed: June 5, 2008
    Publication date: January 15, 2009
    Inventors: Philippe Sansonetti, Stephen Girardin, Dana Philpott, Ivo Boneca
  • Publication number: 20090010964
    Abstract: The invention provides for a method of enhancing immunological responses to an antigen in a vaccine formulation, and for a vaccine formulation that provides for an enhanced immunological response to an antigen. In the method and formulation the antigen is administered with an adjuvant which adjuvant comprises a solution of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas and which adjuvant includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5?3], decosahexaenoic acid [C22: 6?3], ricinoleic acid and derivatives thereof selected from the group consisting of the C1 to C6 alkyl esters thereof, the glycerol-polyethylene glycol esters thereof and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils, such as castor oil with ethylene oxide.
    Type: Application
    Filed: August 3, 2006
    Publication date: January 8, 2009
    Inventors: Anne Grobler, Abraham Frederik Kotze
  • Publication number: 20080311156
    Abstract: The present invention relates to adjuvant compositions which are suitable to be used in vaccines. In particular, the adjuvant compositions of the present invention comprises a saponin and an immunostimulatory oligonucleotide, optionally with a carrier. Also provided by the present invention are vaccines comprising the adjuvants of the present invention and an antigen. Further provided are methods of manufacture of the adjuvants and vaccines of the present invention and their use as medicaments. Methods of treating an individual susceptible to or suffering from a disease by the administration of the vaccines of the present invention are also provided.
    Type: Application
    Filed: July 11, 2008
    Publication date: December 18, 2008
    Inventors: Martin FRIEDE, Nathalie Garcon, Catherine Marie Ghislaine Gerard, Philippe Hermand
  • Publication number: 20080260783
    Abstract: An antigen composition for stimulating an immune response in an inoculated avian species to at least one intestinal pathogenic organism includes naturally-occurring wild Salmonella enterica subspecies in O-serogroups B, C2 and D. Subspecies in O-serogroup B can include Salmonella typhimurium and/or Salmonella agona. Subspecies in O-serogroup C2 can include Salmonella Kentucky. Subspecies in O-serogroup D can include Salmonella enteritidis. The antigen composition can be used alone or in combination with a Marek's Disease vaccine to reduce shedding of E. coli and/or Salmonella bacteria.
    Type: Application
    Filed: February 4, 2008
    Publication date: October 23, 2008
    Inventor: Konky SOTOMAYOR
  • Publication number: 20080260776
    Abstract: The present invention relates to a pharmaceutical composition providing protective unity against a broad spectrum of Salmonella enterica serovars.
    Type: Application
    Filed: May 17, 2005
    Publication date: October 23, 2008
    Inventors: Dirk Bumann, Heiko Apfel
  • Publication number: 20080248066
    Abstract: Free-living microbes are provided in which the nucleic acid has been modified so that the microbe is attenuated for proliferation and/or which comprise genetic mutations that attenuate the ability of the microbe to repair its nucleic acid. Methods of using the modified microbes for the loading, activation, and/or maturation of antigen-presenting cells are also provided. Vaccine compositions comprising the modified microbes and/or the antigen-presenting cells and methods of using the vaccines are also provided. The microbes may be further modified to include heterologous antigens, such as tumor antigens or infectious disease antigens, for use as a vaccine against cancer or infectious diseases.
    Type: Application
    Filed: August 11, 2006
    Publication date: October 9, 2008
    Applicant: Cerus Corporation
    Inventors: Thomas W. Dubensky, Dirk G. Brockstedt, Keith S. Bahjat, John E. Hearst, David N. Cook, William S. Luckett
  • Publication number: 20080220022
    Abstract: The present invention relates to the field of vaccination against Salmonella in animals, particularly avian animals. The present invention also encompasses kits and uses of Salmonella immunogenic compositions or vaccines. The present invention further relates to methods and compositions comprising at least one primo-administration of an attenuated immunogenic composition or vaccine, comprising a pharmaceutically or veterinarily acceptable excipient, diluent or vehicle and at least one attenuated Salmonella, administered to an avian animal before at least one boost-administration of an inactivated immunogenic composition or vaccine, comprising a pharmaceutically or veterinarily acceptable excipient, diluent or vehicle, and at least one inactivated Salmonella.
    Type: Application
    Filed: December 10, 2007
    Publication date: September 11, 2008
    Inventors: Francois-Xavier Le Gros, Stephane Lemiere
  • Publication number: 20080193486
    Abstract: The invention relates to Salmonella typhi Ty21a comprising core-linked Shigella dysenteriae type 1 O-specific polysaccharide (O-Ps) and DNA encoding O antigen biosynthesis, said DNA selected from the group consisting of: a) the DNA sequence set out in any one of SEQ ID NOs: 1 and 2 and species homologs thereof; b) DNA encoding S. dysenteriae polypeptides encoded by any one of SEQ ID NOs: 1 and 2, and species homologs thereof; and c) DNA encoding a O antigen biosynthesis gene product that hybridizes under moderately stringent conditions to the DNA of (a) or (b); and related sequences, compositions of matter, vaccines, methods of using, and methods of making.
    Type: Application
    Filed: May 24, 2005
    Publication date: August 14, 2008
    Inventors: Dennis J. Kopecko, DeQi Xu
  • Patent number: 7404960
    Abstract: A vaccine composition comprising two valences is provided: (i) a first valence which is adjuvant-enhanced with aluminum hydroxide and (ii) a second valence which contains a polysaccharide of bacterial capsule comprising one or more o-acetyl groups and which is not adsorbed with aluminum oxide due to the presence of a protecting compound which may be a phosphate, a citrate or a carbonate and which prevents the adsorption. The first valence can be any vaccine valence. In one particular embodiment, the vaccine composition contains (i) Hepatitis A valence, adsorbed on aluminum hydroxide and (ii) the typhoid fever valence formed by the polysaccharide Vi of the Salmonella typhi capsule.
    Type: Grant
    Filed: July 31, 2002
    Date of Patent: July 29, 2008
    Assignee: Aventis Pasteur SA
    Inventor: Alain Françon
  • Publication number: 20080171064
    Abstract: The present invention relates to live attenuated Salmonella cultures for use as vaccines. The Salmonella cultures of the present invention have a substantially reduced capacity to grow and replicate in the presence of bile. The reduced capacity for growth is due to a metabolic-drift mutation induced by exposure to a combination of nalidixic acid and rifampicin for a time and under conditions sufficient to induce the mutation.
    Type: Application
    Filed: February 14, 2005
    Publication date: July 17, 2008
    Applicant: THE UNIVERSITY OF QUEENSLAND
    Inventor: Tetsuo Mizuno
  • Patent number: 7371393
    Abstract: The present invention provides methods for reducing shedding in an animal. Generally, the method includes administcriirn to an animal a composition including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter.
    Type: Grant
    Filed: March 22, 2006
    Date of Patent: May 13, 2008
    Assignee: Epitopix, LLC
    Inventors: Daryll A. Emery, Darren E. Straub